WO2023087830A1 - Surface coating capable of degrading magnesium and magnesium alloy, and preparation method therefor - Google Patents
Surface coating capable of degrading magnesium and magnesium alloy, and preparation method therefor Download PDFInfo
- Publication number
- WO2023087830A1 WO2023087830A1 PCT/CN2022/115081 CN2022115081W WO2023087830A1 WO 2023087830 A1 WO2023087830 A1 WO 2023087830A1 CN 2022115081 W CN2022115081 W CN 2022115081W WO 2023087830 A1 WO2023087830 A1 WO 2023087830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- phosphate
- calcium
- coating
- magnesium alloy
- Prior art date
Links
- 229910000861 Mg alloy Inorganic materials 0.000 title claims abstract description 75
- 238000000576 coating method Methods 0.000 title claims abstract description 69
- 239000011248 coating agent Substances 0.000 title claims abstract description 65
- 239000011777 magnesium Substances 0.000 title claims abstract description 24
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000593 degrading effect Effects 0.000 title abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract description 30
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical group [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims abstract description 22
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 20
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 20
- 239000010410 layer Substances 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 27
- 229960002261 magnesium phosphate Drugs 0.000 claims description 22
- 239000004137 magnesium phosphate Substances 0.000 claims description 20
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 20
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 8
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical group [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- 239000000956 alloy Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 229960005069 calcium Drugs 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 6
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 6
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 claims description 6
- QQFLQYOOQVLGTQ-UHFFFAOYSA-L magnesium;dihydrogen phosphate Chemical compound [Mg+2].OP(O)([O-])=O.OP(O)([O-])=O QQFLQYOOQVLGTQ-UHFFFAOYSA-L 0.000 claims description 6
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 6
- 229910000401 monomagnesium phosphate Inorganic materials 0.000 claims description 6
- 235000019785 monomagnesium phosphate Nutrition 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 239000003929 acidic solution Substances 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 4
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000388 diammonium phosphate Inorganic materials 0.000 claims description 4
- 235000019838 diammonium phosphate Nutrition 0.000 claims description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 3
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 claims description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 3
- 239000001639 calcium acetate Substances 0.000 claims description 3
- 229960005147 calcium acetate Drugs 0.000 claims description 3
- 235000011092 calcium acetate Nutrition 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- RGROXIVYLKOHIY-UHFFFAOYSA-J dimagnesium;hydrogen phosphate Chemical compound [Mg+2].[Mg+2].OP([O-])([O-])=O.OP([O-])([O-])=O RGROXIVYLKOHIY-UHFFFAOYSA-J 0.000 claims description 3
- -1 heated and soaked Chemical compound 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- MPCRDALPQLDDFX-UHFFFAOYSA-L Magnesium perchlorate Chemical compound [Mg+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O MPCRDALPQLDDFX-UHFFFAOYSA-L 0.000 claims description 2
- 229910019400 Mg—Li Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229960002713 calcium chloride Drugs 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 claims description 2
- 239000011247 coating layer Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
- 239000011654 magnesium acetate Substances 0.000 claims description 2
- 235000011285 magnesium acetate Nutrition 0.000 claims description 2
- 229940069446 magnesium acetate Drugs 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 229960004256 calcium citrate Drugs 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 20
- 238000006731 degradation reaction Methods 0.000 abstract description 20
- 239000007943 implant Substances 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 210000000988 bone and bone Anatomy 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 230000007797 corrosion Effects 0.000 description 6
- 238000005260 corrosion Methods 0.000 description 6
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical group [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 description 2
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 206010016818 Fluorosis Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- DMGNFLJBACZMRM-UHFFFAOYSA-N O[P] Chemical group O[P] DMGNFLJBACZMRM-UHFFFAOYSA-N 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 229910009378 Zn Ca Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005234 chemical deposition Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007739 conversion coating Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 208000004042 dental fluorosis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C22/05—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions
- C23C22/06—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions using aqueous acidic solutions with pH less than 6
- C23C22/07—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions using aqueous acidic solutions with pH less than 6 containing phosphates
- C23C22/08—Orthophosphates
- C23C22/22—Orthophosphates containing alkaline earth metal cations
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C22/05—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions
- C23C22/06—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions using aqueous acidic solutions with pH less than 6
- C23C22/07—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions using aqueous acidic solutions with pH less than 6 containing phosphates
- C23C22/08—Orthophosphates
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C22/05—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions
- C23C22/68—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using aqueous solutions using aqueous solutions with pH between 6 and 8
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C22/73—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals characterised by the process
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C22/82—After-treatment
Definitions
- the invention relates to the technical field of surface coatings of magnesium and magnesium alloys, in particular to a surface coating of degradable magnesium and magnesium alloys and a preparation method thereof.
- the common bone implant materials used in clinical practice are mostly non-degradable stainless steel, titanium alloy, and cobalt-based alloy materials, which remain in the body for a long time after implantation and will stimulate the surrounding body tissues to varying degrees. After recovery, the patient usually needs to undergo a second operation to remove the metal implant, which in turn brings more pain and financial burden to the patient.
- the elastic modulus of these materials is much higher than that of bone tissue, which will lead to the effect of "stress shielding" and affect the repair of bone tissue.
- magnesium alloy Compared with the above traditional implant materials for bone repair, magnesium alloy has the following advantages: 1) It can Degradability, magnesium alloy has a low corrosion potential, it is easy to corrode in the body environment containing chloride ions, and completely degrades in the body in a slow corrosion manner; 2) High biological safety, Mg is an essential nutrient element for the human body, Participate in almost all energy metabolism in the body, and play an important role in neuromotor function, physiological function, and prevention of circulatory system diseases and ischemic heart disease; excessive magnesium will be excreted through urinary system metabolism and decomposition, which has good biological safety; 3) Good biomechanical compatibility. Magnesium is currently the metal material with the closest biomechanical properties to human bone among all metal materials, which can effectively alleviate the clinical "stress shielding" effect of traditional medical metal materials.
- magnesium and magnesium alloys as orthopedic implant materials.
- the chemical properties of magnesium and magnesium alloys are relatively active, and the degradation rate is too fast after implantation in the body. It is difficult to maintain sufficient structural integrity and mechanical strength before tissue repair, regeneration and recovery. Degradation will generate hydrogen gas at the same time. If the degradation is too fast, hydrogen gas will accumulate, which will affect the adhesion and proliferation of surrounding osteoblasts and the healing of bone tissue.
- Calcium-phosphorus coating has a composition similar to that of bone tissue, which can improve the corrosion resistance and biocompatibility of bone implants, and is a commonly used coating.
- hydroxyapatite has good crystallinity and is closest to bone components, which can improve osseointegration ability and accelerate bone tissue healing, and its solubility is the lowest among all kinds of calcium-phosphorus coatings, and the degradation products are slightly alkaline, which is beneficial to prevent corrosion.
- the chemical reaction equilibrium angle further inhibits the magnesium matrix degradation.
- Patent CN106544714B discloses a method for preparing the surface coating of Mg-Zn-Ca magnesium alloy bone screws. The material is subjected to micro-arc electrophoresis treatment and then hydrothermal synthesis treatment to prepare the hydroxyapatite coating. The problem is that there are a large number of micropores and cracks on the surface of the micro-arc electrophoretic coating, which provide ion channels for the infiltration of corrosive media, and directly affect the protection performance of the coating layer against corrosion degradation of the magnesium substrate.
- Patent CN103484845B discloses a ZK60 magnesium alloy calcium-phosphorus coating composite material, which uses a hydrothermal method to synthesize the calcium-phosphorus coating in one step.
- the existing problems and shortcomings are: 1) The fluoride ions produced by the degradation of the magnesium fluoride layer may have a negative impact on the local bone tissue, causing problems such as fluorosis; 2) The preparation process is cumbersome and takes a long time, and brushite needs to be prepared first It is then converted into hydroxyapatite; 3) The production process requires the use of toxic reagents such as high-concentration hydrogen fluoride, which is very dangerous.
- the object of the present invention is to provide a surface coating of degradable magnesium and magnesium alloys and a preparation method thereof in view of the deficiencies in the prior art.
- the first aspect of the present invention is to provide a surface coating of degradable magnesium and magnesium alloys, the surface coating includes an inner layer and an outer layer, the inner layer is a magnesium phosphate conversion layer, and the outer layer is a hydroxyl phosphorus Gray stone coating.
- the magnesium phosphate conversion layer has a thickness of 50 nm-10 ⁇ m
- the hydroxyapatite coating has a thickness of 0.1 ⁇ m-500 ⁇ m.
- the binding force between the surface coating and the magnesium or magnesium alloy substrate is above 50 MPa, and the atomic ratio of Ca/P in the hydroxyapatite coating is 1.5-1.67.
- the second aspect of the present invention provides the preparation method of above-mentioned surface coating, comprises the following steps:
- step S2 The magnesium or magnesium alloy material treated in step S1 is transferred to an alkaline solution containing calcium salt and phosphate, heated and soaked, and a hydroxyapatite coating is formed on the surface of the magnesium phosphate conversion layer.
- the magnesium salt described in step S1 is one or more of magnesium nitrate, magnesium chloride, magnesium sulfate, magnesium phosphate, magnesium perchlorate, magnesium acetate, magnesium hydroxide, and its concentration is 0.001 ⁇ 10 mol /L;
- the phosphate is sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium dihydrogen phosphate, dimagnesium hydrogen phosphate, diammonium hydrogen phosphate, ammonium dihydrogen phosphate, phosphoric acid
- the concentration of which is 0.001 ⁇ 10 mol/L.
- the molar concentration ratio of magnesium ions to phosphate ions in the solution in step S1 is (0.2-5):1, more preferably (0.8-1.2):1.
- the pH of the acidic solution described in step S1 is 2 to 7, and one or more of nitric acid, sulfuric acid, hydrochloric acid, phosphoric acid, and acetic acid are used to adjust the pH; the reaction temperature in step S1 is 5 to 99°C, soaking The time is 5min-12h.
- the phosphate described in step S2 is sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium dihydrogen phosphate, dimagnesium hydrogen phosphate, diammonium hydrogen phosphate, dihydrogen phosphate
- the calcium salt is calcium dihydrogen phosphate, dicalcium phosphate, EDTA-Ca, lemon Calcium Acetate, Calcium Acetate, Calcium Chloride, Calcium Nitrate, Calcium Maleate, Calcium Polyacrylate, Calcium Polymethacrylate, and its concentration is 0.001 ⁇ 10mol/L.
- the molar concentration ratio of the phosphate salt and the calcium salt is (0.2-5):1, more preferably (0.8-1.2):1.
- the pH of the alkaline solution described in step S2 is 7-13, and one or more of sodium hydroxide, potassium hydroxide, and ammonia water is used to adjust the pH; the reaction temperature in step S2 is 5-99°C, Soaking time is 5min-48h.
- the magnesium alloy is Mg-Zn series, Mg-Ca series, Mg-Li series, Mg-Mn series or Mg-Re series bare metal magnesium alloy series without any treatment.
- the present invention adopts the above technical scheme, and compared with the prior art, it has the following technical effects:
- the magnesium alloy coating in the prior art has insufficient ability to control degradation, and it degrades completely within 6 months after being implanted in the body.
- the coating prepared by the invention can control the degradation time of the magnesium alloy implant within 12 to 18 months.
- the coating prepared by the present invention consists of a double-layer structure, the inner layer is a magnesium phosphate conversion layer, and the outer layer is a hydroxyapatite coating with a controllable thickness; the thickness of the hydroxyapatite coating is controllable, and the degradation time can be adjusted according to needs Make adjustments.
- the magnesium alloy coating in the prior art has insufficient bonding strength, and scratches and falls off due to friction during use, especially in the process of screwing in bone nails.
- the coating prepared by the present invention consists of a double-layer structure, wherein the magnesium phosphate conversion layer of the inner layer provides growth sites for the hydroxyapatite coating of the outer layer, effectively improving the bonding force between the coating and the substrate, and the bonding strength can be Up to 50MPa or more.
- the preparation method of the present invention does not require high temperature and high pressure reaction conditions, the production process is simple, the cost is low, and it can be applied to magnesium and magnesium alloy implants with arbitrary complex shapes.
- Fig. 1 is the degradation weight reduction curve figure of coating AZ31 magnesium alloy of the present invention and uncoated AZ31 magnesium alloy;
- FIG. 2 is a CT scan in Verification Example 2.
- AZ31 magnesium alloy is made into a ⁇ 3 ⁇ 10mm sample, polished with 800#, 1200#, 2000# sandpaper in turn, ultrasonically cleaned in anhydrous acetone for 5 minutes to remove the surface oil, and dried after cleaning;
- step 5 Put the AZ31 magnesium alloy sample with magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 95°C, and heat it for 6 hours. After the reaction, take it out and cool down , rinsed with deionized water and dried to obtain a sample with a uniform and complete surface;
- AZ31 magnesium alloy is made into a ⁇ 3 ⁇ 10mm sample, polished with 800#, 1200#, 2000# sandpaper in turn, ultrasonically cleaned in anhydrous acetone for 5 minutes to remove the surface oil, and dried after cleaning;
- step 5 Put the AZ31 magnesium alloy sample with magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 80°C, and heat it for 12 hours. After the reaction, take it out and cool down , rinsed with deionized water and dried to obtain an AZ31 magnesium alloy sample whose surface is evenly covered with white particle coating;
- the bonding force between the coating and the substrate is measured to be 58MPa.
- step 5 Put the K60 magnesium alloy sample with magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 80°C, and heat it for 6 hours. After the reaction is over, take it out and cool down , rinsed with deionized water and dried to obtain a ZK60 magnesium alloy sample with a uniform and complete surface;
- the bonding force between the coating and the substrate is measured at 70MPa using a universal mechanical testing machine.
- step 5 Put the LZ91 magnesium alloy sample with a magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 80°C, and heat it for 12 hours. After the reaction is over, take it out and cool down , rinsed with deionized water and dried to obtain a LZ91 magnesium alloy sample with a uniform and complete surface;
- the bonding force between the coating and the substrate was measured to be 73MPa.
- the samples prepared in the above examples 1 and 2 and the uncoated AZ31 magnesium alloy sample of the same size were placed in a 3% sodium chloride solution, soaked at 37°C for accelerated degradation test. Change the solution every 3-4 days, weigh every week, and observe the surface corrosion and overall degradation of each sample at the same time.
- the obtained weight loss curve is shown in Fig. 1 . It can be seen that the weight of the uncoated magnesium alloy is significantly reduced by more than 50% after immersion for 30 days, while the weight of the magnesium alloys prepared in Example 1 and Example 2 is only reduced by about 10% after immersion for 30 days, indicating that the coating greatly reduces the weight of the magnesium alloy. degradation.
- AZ31 magnesium alloy was processed into a bone nail shape, and coated magnesium alloy screws were prepared according to the method in Example 1. Taking uncoated magnesium alloy screws as a control example, they were respectively implanted in the tibial plateaus of the left and right legs of goats. , CT scans were performed at 3, 6, 12, and 18 months to observe the degradation of magnesium alloy screws. It can be seen from Figure 2 that the uncoated magnesium alloy screw began to degrade immediately after implantation and produced a large amount of gas, forming a cavity in the bone tissue (white arrow in Figure 2). The coated magnesium alloy screws were basically degraded, and no magnesium alloy screws could be seen 12 and 18 months after implantation.
- the existence of the screw can be clearly seen within 12 months after the operation, and the thread structure of the screw remains almost unchanged. After 18 months, the magnesium alloy screw nearly disappears, and it can be seen that The coated magnesium alloy screw of the present invention rarely degrades within 12 months, and degrades completely within 12 to 18 months. It shows that the coating effectively controls the degradation of magnesium alloy in vivo, and the degradation time is controlled within 12-18 months.
Landscapes
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Chemical Treatment Of Metals (AREA)
Abstract
Disclosed in the present invention are a surface coating capable of degrading magnesium and a magnesium alloy, and a preparation method therefor. The surface coating comprises an inner layer and an outer layer; the inner layer is a magnesium phosphate salt conversion layer; and the outer layer is a hydroxyapatite coating. The coating prepared by the present invention is of a double-layer structure, and the magnesium phosphate salt conversion layer of the inner layer provides growth sites for the hydroxyapatite coating of the outer layer, so that the binding force of the coating and a base material is effectively enhanced, and the bonding strength can reach 50 MPa or above. In addition, the thickness of the hydroxyapatite coating is controllable, the degradation time can be adjusted according to needs, and the degradation time of a magnesium alloy implant can be controlled to be 12-18 months.
Description
本发明涉及镁及镁合金的表面涂层技术领域,尤其涉及一种可降解镁及镁合金的表面涂层及其制备方法。 The invention relates to the technical field of surface coatings of magnesium and magnesium alloys, in particular to a surface coating of degradable magnesium and magnesium alloys and a preparation method thereof.
目前常见的用于临床的骨植入材料多为不可降解的不锈钢、钛合金、钴基合金材料,植入后长期留存在体内,会不同程度地刺激周边肌体组织。患者在病愈后通常需经二次手术将金属植入物取出,这又会给患者带来了更多的痛苦和经济负担。另外,这些材料的弹性模量大大超过骨组织,会导致“应力遮挡””效应,影响骨组织修复。与以上几种传统骨修复用植入材料相比,镁合金具有如下优势:1)可降解性,镁合金具有较低的腐蚀电位,在含有氯离子的体内环境下易发生腐蚀,并以缓慢腐蚀的方式在体内完全降解;2)生物安全性高,Mg作为人体必需的营养元素,参与体内几乎所有能量代谢,对神经运动机能、生理机能及预防循环系统疾病和缺血性心脏病均有重要作用;过量的镁会通过泌尿系统代谢分解后排出体外,具有良好的生物安全性;3)生物力学相容性好,镁是目前所有金属材料中生物力学性能与人体骨最接近的金属材料,可有效缓解传统医用金属材料临床上的“应力遮挡”效应。At present, the common bone implant materials used in clinical practice are mostly non-degradable stainless steel, titanium alloy, and cobalt-based alloy materials, which remain in the body for a long time after implantation and will stimulate the surrounding body tissues to varying degrees. After recovery, the patient usually needs to undergo a second operation to remove the metal implant, which in turn brings more pain and financial burden to the patient. In addition, the elastic modulus of these materials is much higher than that of bone tissue, which will lead to the effect of "stress shielding" and affect the repair of bone tissue. Compared with the above traditional implant materials for bone repair, magnesium alloy has the following advantages: 1) It can Degradability, magnesium alloy has a low corrosion potential, it is easy to corrode in the body environment containing chloride ions, and completely degrades in the body in a slow corrosion manner; 2) High biological safety, Mg is an essential nutrient element for the human body, Participate in almost all energy metabolism in the body, and play an important role in neuromotor function, physiological function, and prevention of circulatory system diseases and ischemic heart disease; excessive magnesium will be excreted through urinary system metabolism and decomposition, which has good biological safety; 3) Good biomechanical compatibility. Magnesium is currently the metal material with the closest biomechanical properties to human bone among all metal materials, which can effectively alleviate the clinical "stress shielding" effect of traditional medical metal materials.
但目前镁及镁合金应用到临床上作为骨科内植入物材料尚存在一些问题。镁及镁合金化学性质较为活泼,在植入体内后降解速率过快,在组织修复再生恢复功能前难以保持足够的结构完整性和力学强度。降解同时会产生氢气,若降解过快会引起氢气聚集,影响周围成骨细胞粘附和增殖及骨组织痊愈。However, there are still some problems in the clinical application of magnesium and magnesium alloys as orthopedic implant materials. The chemical properties of magnesium and magnesium alloys are relatively active, and the degradation rate is too fast after implantation in the body. It is difficult to maintain sufficient structural integrity and mechanical strength before tissue repair, regeneration and recovery. Degradation will generate hydrogen gas at the same time. If the degradation is too fast, hydrogen gas will accumulate, which will affect the adhesion and proliferation of surrounding osteoblasts and the healing of bone tissue.
表面涂层目前是一种有效控制镁合金降解的技术手段,目前已有聚合物涂层、羟基磷灰石涂层、氧化镁涂层、钙-磷涂层等多种技术报道。钙-磷涂层拥有与骨组织相近的成分,可提高骨内植物的耐蚀性和生物相容性,是一种常用的涂层。其中羟基磷灰石结晶性好,与骨成分最为接近,能够提高骨整合能力,加速骨组织愈合,并且其溶解度在各类钙-磷涂层中最低,降解产物微碱性,有利于从腐蚀化学反应平衡角度进一步抑制镁基体降解。目前常用化学沉积、电沉积、溶胶凝胶法等在镁合金表面制备羟基磷灰石涂层。然而,大多存在制备工艺复杂,厚度较低或涂层结构不致密,结合强度不足等技术问题。Surface coating is currently an effective technical means to control the degradation of magnesium alloys. At present, there are many technical reports such as polymer coating, hydroxyapatite coating, magnesium oxide coating, and calcium-phosphorus coating. Calcium-phosphorus coating has a composition similar to that of bone tissue, which can improve the corrosion resistance and biocompatibility of bone implants, and is a commonly used coating. Among them, hydroxyapatite has good crystallinity and is closest to bone components, which can improve osseointegration ability and accelerate bone tissue healing, and its solubility is the lowest among all kinds of calcium-phosphorus coatings, and the degradation products are slightly alkaline, which is beneficial to prevent corrosion. The chemical reaction equilibrium angle further inhibits the magnesium matrix degradation. At present, chemical deposition, electrodeposition, sol-gel method, etc. are commonly used to prepare hydroxyapatite coating on the surface of magnesium alloy. However, most of them have technical problems such as complex preparation process, low thickness or non-dense coating structure, and insufficient bonding strength.
专利CN106544714B公开了一种Mg-Zn-Ca镁合金骨螺钉表面涂层的制备方法,将材料微弧电泳处理后再进行水热合成处理,制备羟基磷灰石涂层。存在的问题在于微弧电泳涂层表面存在大量的微孔和裂纹,为腐蚀介质的渗入提供了离子通道,直接影响膜层对镁基体腐蚀降解的保护性能。专利CN103484845B公开一种ZK60镁合金钙磷涂层复合材料,使用水热法一步合成钙磷涂层。但存在问题和不足是:1)这一方法使用的钙源为硝酸钙,体系中没有络合剂存在,不易调节溶液pH值;2)水热温度(100-200℃)过高易影响金属基体力学性能;3)由于羟基磷灰石不易直接在镁及镁合金表面沉积,因此涂层厚度、覆盖率和界面结合强度会有明显欠缺;4)涂层表面无法形成具有更高生物活性的微纳尺度分级结构的复合形貌。CN 111973812A公开了一种镁合金双层涂层的制备方法,内层为氟化镁层,外层为羟基磷灰石转化涂层。存在的问题和不足在于:1)氟化镁层降解产生的氟离子可能会对局部骨组织产生负面影响,造成氟骨病等问题;2)制备过程繁琐时间长,需要先制备透钙磷石再转化为羟基磷灰石;3)生产过程需要使用高浓度氟化氢等有毒试剂,危险性较大。Patent CN106544714B discloses a method for preparing the surface coating of Mg-Zn-Ca magnesium alloy bone screws. The material is subjected to micro-arc electrophoresis treatment and then hydrothermal synthesis treatment to prepare the hydroxyapatite coating. The problem is that there are a large number of micropores and cracks on the surface of the micro-arc electrophoretic coating, which provide ion channels for the infiltration of corrosive media, and directly affect the protection performance of the coating layer against corrosion degradation of the magnesium substrate. Patent CN103484845B discloses a ZK60 magnesium alloy calcium-phosphorus coating composite material, which uses a hydrothermal method to synthesize the calcium-phosphorus coating in one step. But there are problems and deficiencies: 1) the calcium source used in this method is calcium nitrate, and there is no complexing agent in the system, so it is difficult to adjust the pH value of the solution; The mechanical properties of the matrix; 3) Since hydroxyapatite is not easy to deposit directly on the surface of magnesium and magnesium alloys, the thickness, coverage and interfacial bonding strength of the coating will be obviously lacking; 4) The surface of the coating cannot form a higher biological activity. Composite morphology of micro- and nanoscale hierarchical structures. CN 111973812A discloses a method for preparing a magnesium alloy double-layer coating, the inner layer is a magnesium fluoride layer, and the outer layer is a hydroxyapatite conversion coating. The existing problems and shortcomings are: 1) The fluoride ions produced by the degradation of the magnesium fluoride layer may have a negative impact on the local bone tissue, causing problems such as fluorosis; 2) The preparation process is cumbersome and takes a long time, and brushite needs to be prepared first It is then converted into hydroxyapatite; 3) The production process requires the use of toxic reagents such as high-concentration hydrogen fluoride, which is very dangerous.
本发明的目的是针对现有技术中的不足,提供一种可降解镁及镁合金的表面涂层及其制备方法。The object of the present invention is to provide a surface coating of degradable magnesium and magnesium alloys and a preparation method thereof in view of the deficiencies in the prior art.
为实现上述目的,本发明采取的技术方案是:For realizing above-mentioned object, the technical scheme that the present invention takes is:
本发明第一方面是提供一种可降解镁及镁合金的表面涂层,所述表面涂层包括内层和外层,所述内层为磷酸镁盐转化层,所述外层为羟基磷灰石涂层。The first aspect of the present invention is to provide a surface coating of degradable magnesium and magnesium alloys, the surface coating includes an inner layer and an outer layer, the inner layer is a magnesium phosphate conversion layer, and the outer layer is a hydroxyl phosphorus Gray stone coating.
进一步地,所述磷酸镁盐转化层的厚度为50nm-10μm,所述羟基磷灰石涂层的厚度为0.1μm-500μm。Further, the magnesium phosphate conversion layer has a thickness of 50 nm-10 μm, and the hydroxyapatite coating has a thickness of 0.1 μm-500 μm.
进一步地,所述表面涂层与镁或镁合金基材的结合力在50MPa以上,所述羟基磷灰石涂层中Ca/P原子比为1.5-1.67。Further, the binding force between the surface coating and the magnesium or magnesium alloy substrate is above 50 MPa, and the atomic ratio of Ca/P in the hydroxyapatite coating is 1.5-1.67.
本发明第二方面是提供上述表面涂层的制备方法,包括如下步骤:The second aspect of the present invention provides the preparation method of above-mentioned surface coating, comprises the following steps:
S1:将镁或镁合金材料置于含有镁盐和磷酸盐的酸性溶液中加热浸泡,在镁或镁合金材料表面形成磷酸镁盐转化层;S1: heating and soaking magnesium or magnesium alloy material in an acidic solution containing magnesium salt and phosphate, forming a magnesium phosphate conversion layer on the surface of magnesium or magnesium alloy material;
S2:将经步骤S1处理后的镁或镁合金材料转至含有钙盐和磷酸盐的碱性溶液中加热浸泡,在所述磷酸镁盐转化层表面形成羟基磷灰石涂层。S2: The magnesium or magnesium alloy material treated in step S1 is transferred to an alkaline solution containing calcium salt and phosphate, heated and soaked, and a hydroxyapatite coating is formed on the surface of the magnesium phosphate conversion layer.
进一步地,步骤S1中所述的镁盐为硝酸镁、氯化镁、硫酸镁、磷酸镁类、高氯酸镁、乙酸镁、氢氧化镁中的一种或几种,其浓度为0.001~10 mol/L;所述的磷酸盐为磷酸二氢钠、磷酸氢二钠、磷酸二氢钾、磷酸氢二钾、磷酸二氢镁、磷酸氢二镁、磷酸氢二铵、磷酸二氢铵、磷酸二氢钙、磷酸氢二钙中的一种或几种,其浓度为0.001~10 mol/L。Further, the magnesium salt described in step S1 is one or more of magnesium nitrate, magnesium chloride, magnesium sulfate, magnesium phosphate, magnesium perchlorate, magnesium acetate, magnesium hydroxide, and its concentration is 0.001~10 mol /L; the phosphate is sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium dihydrogen phosphate, dimagnesium hydrogen phosphate, diammonium hydrogen phosphate, ammonium dihydrogen phosphate, phosphoric acid One or more of calcium dihydrogen and dicalcium phosphate, the concentration of which is 0.001~10 mol/L.
进一步地,步骤S1中的溶液中的镁离子与磷酸根离子的摩尔浓度比为(0.2~5):1,更优选为(0.8~1.2):1。Further, the molar concentration ratio of magnesium ions to phosphate ions in the solution in step S1 is (0.2-5):1, more preferably (0.8-1.2):1.
进一步地,步骤S1中所述的酸性溶液的pH为2~7,调节pH采用硝酸、硫酸、盐酸、磷酸、乙酸中的一种或几种;步骤S1中反应温度为5~99℃,浸泡时间为5min-12h。Further, the pH of the acidic solution described in step S1 is 2 to 7, and one or more of nitric acid, sulfuric acid, hydrochloric acid, phosphoric acid, and acetic acid are used to adjust the pH; the reaction temperature in step S1 is 5 to 99°C, soaking The time is 5min-12h.
进一步地,步骤S2中所述的磷酸盐为磷酸二氢钠、磷酸氢二钠、磷酸二氢钾、磷酸氢二钾、磷酸二氢镁、磷酸氢二镁、磷酸氢二铵、磷酸二氢铵、磷酸二氢钙、磷酸氢二钙中的一种或几种,其浓度为0.001~10 mol/L;所述的钙盐为磷酸二氢钙、磷酸氢二钙、EDTA-Ca、柠檬酸钙、乙酸钙、氯化钙、硝酸钙、马来酸钙、聚丙烯酸钙、聚甲基丙烯酸钙中的一种或几种,其浓度为0.001~10mol/L。Further, the phosphate described in step S2 is sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium dihydrogen phosphate, dimagnesium hydrogen phosphate, diammonium hydrogen phosphate, dihydrogen phosphate One or more of ammonium, calcium dihydrogen phosphate, and dicalcium phosphate, the concentration of which is 0.001~10 mol/L; the calcium salt is calcium dihydrogen phosphate, dicalcium phosphate, EDTA-Ca, lemon Calcium Acetate, Calcium Acetate, Calcium Chloride, Calcium Nitrate, Calcium Maleate, Calcium Polyacrylate, Calcium Polymethacrylate, and its concentration is 0.001~10mol/L.
进一步地,所述磷酸盐和钙盐的摩尔浓度比为(0.2~5):1,更优选为(0.8~1.2):1。Further, the molar concentration ratio of the phosphate salt and the calcium salt is (0.2-5):1, more preferably (0.8-1.2):1.
进一步地,步骤S2中所述的碱性溶液的pH为7~13,调节pH采用氢氧化钠、氢氧化钾、氨水中的一种或几种;步骤S2中反应温度为5~99℃,浸泡时间为5min-48h。Further, the pH of the alkaline solution described in step S2 is 7-13, and one or more of sodium hydroxide, potassium hydroxide, and ammonia water is used to adjust the pH; the reaction temperature in step S2 is 5-99°C, Soaking time is 5min-48h.
进一步地,所述镁合金为Mg-Zn系、Mg-Ca系、Mg-Li系、Mg-Mn系或Mg-Re系未经任何处理的裸金属镁合金系列。Further, the magnesium alloy is Mg-Zn series, Mg-Ca series, Mg-Li series, Mg-Mn series or Mg-Re series bare metal magnesium alloy series without any treatment.
本发明采用以上技术方案,与现有技术相比,具有如下技术效果:The present invention adopts the above technical scheme, and compared with the prior art, it has the following technical effects:
1)现有技术中的镁合金涂层控制降解能力不足,在植入体内后多在6个月内完全降解。本发明制备的涂层可将镁合金植入物的降解时间控制在12~18个月。1) The magnesium alloy coating in the prior art has insufficient ability to control degradation, and it degrades completely within 6 months after being implanted in the body. The coating prepared by the invention can control the degradation time of the magnesium alloy implant within 12 to 18 months.
2)现有技术中的镁合金涂层多为单层涂层,厚度、均匀性不易控制,降解时间不受控。本发明制备的涂层由双层结构组成,内层为磷酸镁盐转化层,外层为厚度可控的羟基磷灰石涂层;羟基磷灰石涂层厚度可控,降解时间可根据需要进行调节。2) Most of the magnesium alloy coatings in the prior art are single-layer coatings, and the thickness and uniformity are not easy to control, and the degradation time is not controlled. The coating prepared by the present invention consists of a double-layer structure, the inner layer is a magnesium phosphate conversion layer, and the outer layer is a hydroxyapatite coating with a controllable thickness; the thickness of the hydroxyapatite coating is controllable, and the degradation time can be adjusted according to needs Make adjustments.
3)现有技术中的镁合金涂层结合强度不足,在使用的过程中由于摩擦导致剐蹭、脱落,尤其是在骨钉拧入等过程中。本发明制备的涂层由双层结构组成,其中内层的磷酸镁盐转化层为外层的羟基磷灰石涂层提供生长位点,有效提高涂层与基材的结合力,结合强度可达50MPa以上。3) The magnesium alloy coating in the prior art has insufficient bonding strength, and scratches and falls off due to friction during use, especially in the process of screwing in bone nails. The coating prepared by the present invention consists of a double-layer structure, wherein the magnesium phosphate conversion layer of the inner layer provides growth sites for the hydroxyapatite coating of the outer layer, effectively improving the bonding force between the coating and the substrate, and the bonding strength can be Up to 50MPa or more.
4)本发明的制备方法无需高温高压的反应条件,生产过程简单,成本低,并可适用于任意复杂形状的镁及镁合金内植物器械。4) The preparation method of the present invention does not require high temperature and high pressure reaction conditions, the production process is simple, the cost is low, and it can be applied to magnesium and magnesium alloy implants with arbitrary complex shapes.
图1为本发明的涂层AZ31镁合金与无涂层AZ31镁合金的降解重量减少曲线图; Fig. 1 is the degradation weight reduction curve figure of coating AZ31 magnesium alloy of the present invention and uncoated AZ31 magnesium alloy;
图2为验证例2中的CT扫描图。FIG. 2 is a CT scan in Verification Example 2.
下面结合附图和具体实施例对本发明作进一步说明,但不作为本发明的限定。需要说明的是,在不冲突的情况下,本发明中的实施例及实施例中的特征可以相互组合。The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, but not as a limitation of the present invention. It should be noted that, in the case of no conflict, the embodiments of the present invention and the features in the embodiments can be combined with each other.
实施例Example
1 1
在AZ31镁合金棒材表面制备可控降解涂层,具体步骤如下:Prepare a controllable degradable coating on the surface of AZ31 magnesium alloy rods, the specific steps are as follows:
1)首先将AZ31镁合金制成Φ3×10mm试样,依次用800#,1200#,2000#砂纸打磨,在无水丙酮中超声清洗5min取出表面油污,清洗后吹干;1) First, AZ31 magnesium alloy is made into a Φ3×10mm sample, polished with 800#, 1200#, 2000# sandpaper in turn, ultrasonically cleaned in anhydrous acetone for 5 minutes to remove the surface oil, and dried after cleaning;
2)配制含0.25mol/L硝酸镁和0.25mol/L磷酸二氢钠的溶液,使用稀硝酸将溶液的pH调至3.5,水浴加热至75℃;2) Prepare a solution containing 0.25mol/L magnesium nitrate and 0.25mol/L sodium dihydrogen phosphate, adjust the pH of the solution to 3.5 with dilute nitric acid, and heat it in a water bath to 75°C;
3)将AZ31镁合金试样放入加热好的溶液中,浸泡反应60分钟,然后取出使用去离子水冲洗,晾干,得到具有磷酸镁盐转化层的AZ31镁合金试样;3) Put the AZ31 magnesium alloy sample into the heated solution, soak and react for 60 minutes, then take it out and rinse it with deionized water, and dry it to obtain the AZ31 magnesium alloy sample with a magnesium phosphate conversion layer;
4)配制含0.25mol/L柠檬酸钙和0.25mol/L磷酸二氢钠的溶液,使用氢氧化钠将pH调至9.5;4) Prepare a solution containing 0.25mol/L calcium citrate and 0.25mol/L sodium dihydrogen phosphate, and use sodium hydroxide to adjust the pH to 9.5;
5)将步骤3)中得到的具有磷酸镁盐转化层的AZ31镁合金试样放入步骤4)配制的溶液中,放入水浴加热至95℃,加热反应6小时,反应结束后,取出降温,用去离子水冲洗后干燥,得到的表面均匀完整的试样;5) Put the AZ31 magnesium alloy sample with magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 95°C, and heat it for 6 hours. After the reaction, take it out and cool down , rinsed with deionized water and dried to obtain a sample with a uniform and complete surface;
6)使用万能力学试验机测得涂层与基材的结合力为63MPa。6) The bonding force between the coating and the substrate was measured to be 63MPa using a universal mechanical testing machine.
实施例Example
22
在AZ31镁合金棒材表面制备可控降解涂层,具体步骤如下:Prepare a controllable degradable coating on the surface of AZ31 magnesium alloy rods, the specific steps are as follows:
1)首先将AZ31镁合金制成Φ3×10mm试样,依次用800#,1200#,2000#砂纸打磨,在无水丙酮中超声清洗5min取出表面油污,清洗后吹干;1) First, AZ31 magnesium alloy is made into a Φ3×10mm sample, polished with 800#, 1200#, 2000# sandpaper in turn, ultrasonically cleaned in anhydrous acetone for 5 minutes to remove the surface oil, and dried after cleaning;
2)配制含0.5mol/L硫酸镁和0.5mol/L磷酸二氢钾的溶液,使用稀硫酸将溶液的pH调至2.5,水浴加热至60℃;2) Prepare a solution containing 0.5 mol/L magnesium sulfate and 0.5 mol/L potassium dihydrogen phosphate, adjust the pH of the solution to 2.5 with dilute sulfuric acid, and heat it in a water bath to 60°C;
3)将AZ31镁合金试样放入加热好的溶液中,浸泡反应120分钟,然后取出使用去离子水冲洗,晾干,得到具有磷酸镁盐转化层的AZ31镁合金试样;3) Put the AZ31 magnesium alloy sample into the heated solution, soak and react for 120 minutes, then take it out and rinse it with deionized water, and dry it to obtain the AZ31 magnesium alloy sample with a magnesium phosphate conversion layer;
4)配制含0.15mol/L
EDTA-Ca钙和0.15mol/L磷酸二氢钾的溶液,使用氢氧化钾将pH调至9.0;4) Preparation containing 0.15mol/L
EDTA-Ca calcium and 0.15mol/L potassium dihydrogen phosphate solution, use potassium hydroxide to adjust the pH to 9.0;
5)将步骤3)中得到的具有磷酸镁盐转化层的AZ31镁合金试样放入步骤4)配制的溶液中,放入水浴加热至80℃,加热反应12小时,反应结束后,取出降温,用去离子水冲洗后干燥,得到的表面均匀布满白色颗粒涂层的AZ31镁合金试样;5) Put the AZ31 magnesium alloy sample with magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 80°C, and heat it for 12 hours. After the reaction, take it out and cool down , rinsed with deionized water and dried to obtain an AZ31 magnesium alloy sample whose surface is evenly covered with white particle coating;
6)使用万能力学试验机测得涂层与基材的结合力为58MPa。6) Using a universal mechanical testing machine, the bonding force between the coating and the substrate is measured to be 58MPa.
实施例Example
33
在ZK60镁合金棒材表面制备可控降解涂层,具体步骤如下:Prepare a controllable degradable coating on the surface of ZK60 magnesium alloy rods, the specific steps are as follows:
1)首先将ZK60镁合金制成Φ3×10mm试样,依次用800#,1200#,2000#砂纸打磨,在无水丙酮中超声清洗5min取出表面油污,清洗后吹干;1) First, make a Φ3×10mm sample of ZK60 magnesium alloy, polish it with 800#, 1200#, 2000# sandpaper in turn, and ultrasonically clean it in anhydrous acetone for 5 minutes to remove the surface oil, and then dry it after cleaning;
2)配制含0.25mol/L磷酸二氢镁的溶液,使用磷酸将溶液的pH调至3.0,水浴加热至70℃;2) Prepare a solution containing 0.25 mol/L magnesium dihydrogen phosphate, adjust the pH of the solution to 3.0 with phosphoric acid, and heat to 70°C in a water bath;
3)将ZK60镁合金试样放入加热好的溶液中,浸泡反应45分钟,然后取出使用去离子水冲洗,晾干,得到具有磷酸镁盐转化层的K60镁合金试样;3) Put the ZK60 magnesium alloy sample into the heated solution, soak and react for 45 minutes, then take it out and rinse it with deionized water, and dry it to obtain a K60 magnesium alloy sample with a magnesium phosphate conversion layer;
4)配制含0.10mol/L
柠檬酸钙和0.10mol/L磷酸二氢钠的溶液,使用氢氧化钠将pH调至9.0;4) Preparation containing 0.10mol/L
A solution of calcium citrate and 0.10 mol/L sodium dihydrogen phosphate, using sodium hydroxide to adjust the pH to 9.0;
5)将步骤3)中得到的具有磷酸镁盐转化层的K60镁合金试样放入步骤4)配制的溶液中,放入水浴加热至80℃,加热反应6小时,反应结束后,取出降温,用去离子水冲洗后干燥,得到的表面均匀完整的ZK60镁合金试样;5) Put the K60 magnesium alloy sample with magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 80°C, and heat it for 6 hours. After the reaction is over, take it out and cool down , rinsed with deionized water and dried to obtain a ZK60 magnesium alloy sample with a uniform and complete surface;
6)使用万能力学试验机测得涂层与基材的结合力为70MPa。6) The bonding force between the coating and the substrate is measured at 70MPa using a universal mechanical testing machine.
实施例Example
44
在LZ91镁合金棒材表面制备可控降解涂层,具体步骤如下:Prepare a controllable degradable coating on the surface of LZ91 magnesium alloy rods, the specific steps are as follows:
1)首先将LZ91镁合金制成Φ3×10mm试样,依次用800#,1200#,2000#砂纸打磨,在无水丙酮中超声清洗5min取出表面油污,清洗后吹干;1) First, make LZ91 magnesium alloy into a Φ3×10mm sample, polish it with 800#, 1200#, 2000# sandpaper in turn, and ultrasonically clean it in anhydrous acetone for 5 minutes to remove the surface oil, and then dry it after cleaning;
2)配制含0.35mol/L磷酸二氢镁的溶液,使用磷酸将溶液的pH调至3.0,水浴加热至75℃;2) Prepare a solution containing 0.35 mol/L magnesium dihydrogen phosphate, adjust the pH of the solution to 3.0 with phosphoric acid, and heat it in a water bath to 75°C;
3)将LZ91镁合金试样放入加热好的溶液中,浸泡反应60分钟,然后取出使用去离子水冲洗,晾干,得到具有磷酸镁盐转化层的LZ91镁合金试样;3) Put the LZ91 magnesium alloy sample into the heated solution, soak and react for 60 minutes, then take it out and rinse it with deionized water, and dry it to obtain a LZ91 magnesium alloy sample with a magnesium phosphate conversion layer;
4)配制含0.15mol/L
EDTA-Ca和0.15mol/L磷酸二氢钠的溶液,使用氢氧化钠将pH调至7.5;4) Preparation containing 0.15mol/L
EDTA-Ca and 0.15mol/L sodium dihydrogen phosphate solution, use sodium hydroxide to adjust the pH to 7.5;
5)将步骤3)中得到的具有磷酸镁盐转化层的LZ91镁合金试样放入步骤4)配制的溶液中,放入水浴加热至80℃,加热反应12小时,反应结束后,取出降温,用去离子水冲洗后干燥,得到的表面均匀完整的LZ91镁合金试样;5) Put the LZ91 magnesium alloy sample with a magnesium phosphate conversion layer obtained in step 3) into the solution prepared in step 4), put it in a water bath and heat it to 80°C, and heat it for 12 hours. After the reaction is over, take it out and cool down , rinsed with deionized water and dried to obtain a LZ91 magnesium alloy sample with a uniform and complete surface;
6)使用万能力学试验机测得涂层与基材的结合力为73MPa。6) Using a universal mechanical testing machine, the bonding force between the coating and the substrate was measured to be 73MPa.
验证例Verification example
11
将上述实施例1和实例2制得的试样及同样尺寸无涂层AZ31镁合金试样放入质量分数为3%的氯化钠溶液中,在37℃下浸泡进行加速降解测试。每3-4天更换溶液,每周称重,同时观察各个试样的表面腐蚀以及整体降解的情况。得到的失重曲线如图1。可见无涂层镁合金在浸泡30天后,重量大幅减少50%以上,而实例1和实例2中制得的镁合金在浸泡30天后,重量仅减少10%左右,说明涂层大大降低了镁合金的降解。The samples prepared in the above examples 1 and 2 and the uncoated AZ31 magnesium alloy sample of the same size were placed in a 3% sodium chloride solution, soaked at 37°C for accelerated degradation test. Change the solution every 3-4 days, weigh every week, and observe the surface corrosion and overall degradation of each sample at the same time. The obtained weight loss curve is shown in Fig. 1 . It can be seen that the weight of the uncoated magnesium alloy is significantly reduced by more than 50% after immersion for 30 days, while the weight of the magnesium alloys prepared in Example 1 and Example 2 is only reduced by about 10% after immersion for 30 days, indicating that the coating greatly reduces the weight of the magnesium alloy. degradation.
验证例Verification example
22
将AZ31镁合金加工成骨钉状,按照实施例1中的方法制得涂层镁合金螺钉,以无涂层镁合金螺钉为对照例,分别植入山羊的左腿和右腿的胫骨平台处,在3、6、12、18个月进行CT扫描观察镁合金螺钉的降解情况。从图2中可看出,无涂层镁合金螺钉在植入后即开始降解并产生大量气体,在骨组织中形成空洞(图2中白色箭头处),在植入后6个月,无涂层镁合金螺钉基本降解完毕,在植入后12、18个月已看不到镁合金螺钉的存在。而本发明的涂层镁合金螺钉,在术后12个月内均可明显看到螺钉的存在,且螺钉的螺纹结构保持几乎不变,在18个月后镁合金螺钉接近消失,可看出本发明涂层镁合金螺钉在12个月内很少降解,并在12~18个月内降解完毕。说明,涂层有效控制了镁合金在体内的降解,并将降解时间控制在12~18个月内。AZ31 magnesium alloy was processed into a bone nail shape, and coated magnesium alloy screws were prepared according to the method in Example 1. Taking uncoated magnesium alloy screws as a control example, they were respectively implanted in the tibial plateaus of the left and right legs of goats. , CT scans were performed at 3, 6, 12, and 18 months to observe the degradation of magnesium alloy screws. It can be seen from Figure 2 that the uncoated magnesium alloy screw began to degrade immediately after implantation and produced a large amount of gas, forming a cavity in the bone tissue (white arrow in Figure 2). The coated magnesium alloy screws were basically degraded, and no magnesium alloy screws could be seen 12 and 18 months after implantation. However, for the coated magnesium alloy screw of the present invention, the existence of the screw can be clearly seen within 12 months after the operation, and the thread structure of the screw remains almost unchanged. After 18 months, the magnesium alloy screw nearly disappears, and it can be seen that The coated magnesium alloy screw of the present invention rarely degrades within 12 months, and degrades completely within 12 to 18 months. It shows that the coating effectively controls the degradation of magnesium alloy in vivo, and the degradation time is controlled within 12-18 months.
上所述仅为本发明较佳的实施例,并非因此限制本发明的实施方式及保护范围,对于本领域技术人员而言,应当能够意识到凡运用本发明说明书内容及图示所作出的等同替换和显而易见的变化所得到的方案,均应当包含在本发明的保护范围内。The above are only preferred embodiments of the present invention, and are not intended to limit the implementation and protection scope of the present invention. For those skilled in the art, they should be able to realize that all equivalents made by using the contents of the description and illustrations of the present invention The solutions obtained by replacement and obvious changes shall all be included in the protection scope of the present invention.
Claims (10)
- 一种可降解镁及镁合金的表面涂层,其特征在于,所述表面涂层包括内层和外层,所述内层为磷酸镁盐转化层,所述外层为羟基磷灰石涂层。A surface coating for degradable magnesium and magnesium alloys, characterized in that the surface coating includes an inner layer and an outer layer, the inner layer is a magnesium phosphate conversion layer, and the outer layer is a hydroxyapatite coating layer.
- 根据权利要求1所述的表面涂层,其特征在于,所述磷酸镁盐转化层的厚度为50nm-10μm,所述羟基磷灰石涂层的厚度为0.1μm-500μm。The surface coating according to claim 1, characterized in that, the magnesium phosphate conversion layer has a thickness of 50 nm-10 μm, and the hydroxyapatite coating has a thickness of 0.1 μm-500 μm.
- 根据权利要求1所述的表面涂层,其特征在于,所述表面涂层与镁或镁合金基材的结合力在50MPa以上,所述羟基磷灰石涂层中Ca/P原子比为1.5-1.67。The surface coating according to claim 1, wherein the binding force between the surface coating and the magnesium or magnesium alloy substrate is above 50MPa, and the Ca/P atomic ratio in the hydroxyapatite coating is 1.5 -1.67.
- 一种如权利要求1-3任一项所述的表面涂层的制备方法,其特征在于,包括如下步骤:A method for preparing a surface coating as claimed in any one of claims 1-3, comprising the steps of:S1:将镁或镁合金材料置于含有镁盐和磷酸盐的酸性溶液中加热浸泡,在镁或镁合金材料表面形成磷酸镁盐转化层;S1: heating and soaking magnesium or magnesium alloy material in an acidic solution containing magnesium salt and phosphate, forming a magnesium phosphate conversion layer on the surface of magnesium or magnesium alloy material;S2:将经步骤S1处理后的镁或镁合金材料转至含有钙盐和磷酸盐的碱性溶液中加热浸泡,在所述磷酸镁盐转化层表面形成羟基磷灰石涂层。S2: The magnesium or magnesium alloy material treated in step S1 is transferred to an alkaline solution containing calcium salt and phosphate, heated and soaked, and a hydroxyapatite coating is formed on the surface of the magnesium phosphate conversion layer.
- 根据权利要求4所述的制备方法,其特征在于,步骤S1中所述的镁盐为硝酸镁、氯化镁、硫酸镁、磷酸镁类、高氯酸镁、乙酸镁、氢氧化镁中的一种或几种,其浓度为0.001~10 mol/L;所述的磷酸盐为磷酸二氢钠、磷酸氢二钠、磷酸二氢钾、磷酸氢二钾、磷酸二氢镁、磷酸氢二镁、磷酸氢二铵、磷酸二氢铵、磷酸二氢钙、磷酸氢二钙中的一种或几种,其浓度为0.001~10 mol/L。The preparation method according to claim 4, wherein the magnesium salt described in step S1 is one of magnesium nitrate, magnesium chloride, magnesium sulfate, magnesium phosphate, magnesium perchlorate, magnesium acetate, and magnesium hydroxide Or several, its concentration is 0.001~10 mol/L; Described phosphate is sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium dihydrogen phosphate, dimagnesium hydrogen phosphate, One or more of diammonium hydrogen phosphate, ammonium dihydrogen phosphate, calcium dihydrogen phosphate, and dicalcium hydrogen phosphate, the concentration of which is 0.001~10 mol/L.
- 根据权利要求5所述的制备方法,其特征在于,步骤S1中的溶液中的镁离子与磷酸根离子的摩尔浓度比为(0.2~5):1。The preparation method according to claim 5, characterized in that the molar concentration ratio of magnesium ions to phosphate ions in the solution in step S1 is (0.2-5):1.
- 根据权利要求4所述的制备方法,其特征在于,步骤S1中所述的酸性溶液的pH为2~7,调节pH采用硝酸、硫酸、盐酸、磷酸、乙酸中的一种或几种;步骤S1中反应温度为5~99℃,浸泡时间为5min-12h。The preparation method according to claim 4, wherein the pH of the acidic solution described in step S1 is 2 to 7, and one or more of nitric acid, sulfuric acid, hydrochloric acid, phosphoric acid, and acetic acid are used to adjust the pH; step The reaction temperature in S1 is 5~99℃, and the soaking time is 5min-12h.
- 根据权利要求4所述的制备方法,其特征在于,步骤S2中所述的磷酸盐为磷酸二氢钠、磷酸氢二钠、磷酸二氢钾、磷酸氢二钾、磷酸二氢镁、磷酸氢二镁、磷酸氢二铵、磷酸二氢铵、磷酸二氢钙、磷酸氢二钙中的一种或几种,其浓度为0.001~10 mol/L;所述的钙盐为磷酸二氢钙、磷酸氢二钙、EDTA-Ca、柠檬酸钙、乙酸钙、氯化钙、硝酸钙、马来酸钙、聚丙烯酸钙、聚甲基丙烯酸钙中的一种或几种,其浓度为0.001~10mol/L;所述磷酸盐和钙盐的摩尔浓度比为(0.2~5):1。The preparation method according to claim 4, wherein the phosphate described in step S2 is sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium dihydrogen phosphate, hydrogen phosphate One or more of dimagnesium, diammonium hydrogen phosphate, ammonium dihydrogen phosphate, calcium dihydrogen phosphate, and dicalcium hydrogen phosphate, the concentration of which is 0.001~10 mol/L; the calcium salt is calcium dihydrogen phosphate , dicalcium hydrogen phosphate, EDTA-Ca, calcium citrate, calcium acetate, calcium chloride, calcium nitrate, calcium maleate, calcium polyacrylate, calcium polymethacrylate, the concentration is 0.001 ~10mol/L; the molar concentration ratio of the phosphate and calcium salt is (0.2~5):1.
- 根据权利要求4所述的制备方法,其特征在于,步骤S2中所述的碱性溶液的pH为7~13,调节pH采用氢氧化钠、氢氧化钾、氨水中的一种或几种;步骤S2中反应温度为5~99℃,浸泡时间为5min-48h。The preparation method according to claim 4, wherein the pH of the alkaline solution described in step S2 is 7 to 13, and one or more of sodium hydroxide, potassium hydroxide, and ammonia are used to adjust the pH; In step S2, the reaction temperature is 5-99°C, and the soaking time is 5min-48h.
- 根据权利要求4所述的制备方法,其特征在于,所述镁合金为Mg-Zn系、Mg-Ca系、Mg-Li系、Mg-Mn系或Mg-Re系未经任何处理的裸金属镁合金系列。The preparation method according to claim 4, characterized in that the magnesium alloy is a bare metal of Mg-Zn system, Mg-Ca system, Mg-Li system, Mg-Mn system or Mg-Re system without any treatment Magnesium alloy series.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/175,609 US20230212755A1 (en) | 2021-11-18 | 2023-02-28 | Surface coating for degradable magnesium and magnesium alloys and method for preparing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111370263.8A CN114622193A (en) | 2021-11-18 | 2021-11-18 | Surface coating capable of degrading magnesium and magnesium alloy and preparation method thereof |
CN202111370263.8 | 2021-11-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/175,609 Continuation US20230212755A1 (en) | 2021-11-18 | 2023-02-28 | Surface coating for degradable magnesium and magnesium alloys and method for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023087830A1 true WO2023087830A1 (en) | 2023-05-25 |
Family
ID=81896653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/115081 WO2023087830A1 (en) | 2021-11-18 | 2022-08-26 | Surface coating capable of degrading magnesium and magnesium alloy, and preparation method therefor |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230212755A1 (en) |
CN (1) | CN114622193A (en) |
WO (1) | WO2023087830A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114622193A (en) * | 2021-11-18 | 2022-06-14 | 上海宛文创业孵化器管理合伙企业(有限合伙) | Surface coating capable of degrading magnesium and magnesium alloy and preparation method thereof |
CN115252916A (en) * | 2022-07-22 | 2022-11-01 | 大博医疗科技股份有限公司 | Medical hollow magnesium or magnesium alloy implant and preparation method thereof |
CN116925414B (en) * | 2023-08-02 | 2024-06-14 | 上海双申医疗器械股份有限公司 | Surface modified polyether-ether-ketone material and surface modification method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101302638A (en) * | 2008-01-07 | 2008-11-12 | 郑州大学 | Preparation of nano-HAP coating/magnesium alloy composite biological material |
CN101461964A (en) * | 2007-12-19 | 2009-06-24 | 中国科学院金属研究所 | Bioactivity surface modification method of biological medical degradable magnesium alloy |
US20130261735A1 (en) * | 2012-03-30 | 2013-10-03 | Abbott Cardiovascular Systems Inc. | Magnesium alloy implants with controlled degradation |
CN107789665A (en) * | 2017-10-31 | 2018-03-13 | 重庆理工大学 | A kind of preparation method of the super-hydrophobic hydroxyapatite film layer of Mg alloy surface |
CN114622193A (en) * | 2021-11-18 | 2022-06-14 | 上海宛文创业孵化器管理合伙企业(有限合伙) | Surface coating capable of degrading magnesium and magnesium alloy and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105274603B (en) * | 2015-11-27 | 2018-03-16 | 福州大学 | Composite modified coating of magnesium or Mg alloy surface carbon nanotubes and preparation method thereof |
-
2021
- 2021-11-18 CN CN202111370263.8A patent/CN114622193A/en active Pending
-
2022
- 2022-08-26 WO PCT/CN2022/115081 patent/WO2023087830A1/en unknown
-
2023
- 2023-02-28 US US18/175,609 patent/US20230212755A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101461964A (en) * | 2007-12-19 | 2009-06-24 | 中国科学院金属研究所 | Bioactivity surface modification method of biological medical degradable magnesium alloy |
CN101302638A (en) * | 2008-01-07 | 2008-11-12 | 郑州大学 | Preparation of nano-HAP coating/magnesium alloy composite biological material |
US20130261735A1 (en) * | 2012-03-30 | 2013-10-03 | Abbott Cardiovascular Systems Inc. | Magnesium alloy implants with controlled degradation |
CN107789665A (en) * | 2017-10-31 | 2018-03-13 | 重庆理工大学 | A kind of preparation method of the super-hydrophobic hydroxyapatite film layer of Mg alloy surface |
CN114622193A (en) * | 2021-11-18 | 2022-06-14 | 上海宛文创业孵化器管理合伙企业(有限合伙) | Surface coating capable of degrading magnesium and magnesium alloy and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
"Doctoral Dissertation", 1 November 2020, JILIN UNIVERSITY, CN, article ZAI, WEI: "Study on Preparation and Performance of Bioactive Phosphate Coatings on Mg Alloys", pages: 1 - 149, XP009545680, DOI: 10.27162/d.cnki.gjlin.2020.007315 * |
ZHOU, HAILI ET AL.: "Calcium phosphate coating on biomedical WE43 magnesium alloy pretreated with a magnesium phosphate layer for corrosion protection", SURFACE & COATINGS TECHNOLOGY, vol. 401, 30 July 2020 (2020-07-30), XP086323892, ISSN: 0257-8972, DOI: 10.1016/j.surfcoat.2020.126248 * |
Also Published As
Publication number | Publication date |
---|---|
CN114622193A (en) | 2022-06-14 |
US20230212755A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023087830A1 (en) | Surface coating capable of degrading magnesium and magnesium alloy, and preparation method therefor | |
Sasikumar et al. | Surface modification methods for titanium and its alloys and their corrosion behavior in biological environment: a review | |
Dorozhkin | Calcium orthophosphate coatings on magnesium and its biodegradable alloys | |
CN103933611B (en) | The preparation method of medical magnesium alloy surface hydroxyapatite/polylactic acid composite coating | |
Yang et al. | The order of calcium and phosphate ion deposition on chemically treated titanium surfaces soaked in aqueous solution | |
Yajing et al. | Magnesium substituted hydroxyapatite coating on titanium with nanotublar TiO2 intermediate layer via electrochemical deposition | |
JP5757943B2 (en) | Implant coated with reticulated or island-like low crystalline hydroxide apatite and coating method thereof | |
CN111973812B (en) | Hydroxyapatite coating with bioactivity and hierarchical structure on surface of degradable magnesium-based endosteal implant and preparation method thereof | |
CN108939155B (en) | Magnesium-based tissue engineering material antibacterial coating and preparation method thereof | |
CN104623739A (en) | Coated magnesium alloy bone nails, bone plates and cancellous bone screws and preparation method thereof | |
CN103505763A (en) | Surface coating for magnesium alloy intra-bony fixing products and preparation method thereof | |
CN101642585B (en) | Biological activating solution for surface of magnesium alloy and application thereof | |
JP3803140B2 (en) | Dental implant and method for manufacturing dental implant | |
CN114533955B (en) | Medical magnesium alloy surface coating with strong binding force and preparation method thereof | |
Zhai et al. | Fluoride coatings on magnesium alloy implants | |
CN109537025B (en) | Metal composite material containing corrosion-resistant coating, degradable magnesium alloy bone screw and application | |
CN108004527A (en) | A kind of preparation method of zinc doping hydroxyapatite coating layer for magnesium alloy materials | |
CN105327397B (en) | A kind of preparation of the degradable implantation material of the mesoporous calcium silicates coating of medical magnesium alloy surface | |
CN110624128B (en) | Degradable magnesium-based bone repair material calcium-phosphorus strontium-doped functional coating and preparation thereof | |
CN104274863A (en) | Medical implant of magnesium alloy/conversion coating and preparation method of medical implant | |
CN112121227A (en) | Preparation method of medical composite coating of strontium titanate/strontium hydroxyapatite on titanium metal surface | |
CN115501392B (en) | Zinc oxide/zinc phosphate nano rod composite antibacterial coating and preparation method and application thereof | |
KR20120101748A (en) | An implant treatment solution and a method using thereof and an implant manufactured thereby | |
Fatehi et al. | Biomimetic hydroxyapatite coatings deposited onto heat and alkali treated Ti6Al4V surface | |
CN109646717B (en) | Magnesium alloy surface nano hydroxyapatite coating based on ultrasound and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22894371 Country of ref document: EP Kind code of ref document: A1 |